Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 116

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 116
---
 service debt obligations and could result in operating and financial covenants that restrict NewGenIvf’s operations and its ability to pay dividends to its shareholders. If NewGenIvf is unable to obtain additional equity or debt financing as required, its business operations and prospects may suffer. Please see “ Risk Factors — Risks Relating to NewGenIvf’s Business and Industry — NewGenIvf requires a significant amount of capital to fund its operations and growth. If NewGenIvf cannot obtain sufficient capital on acceptable terms, its business, financial condition, and prospects may be materially and adversely affected.”

The following table presents NewGenIvf’s selected consolidated cash flow data for the periods indicated.

|                                                                     |     | For the Year ended 
 December 31,       
 2024               |            |   |     | 2023 |            |   |
|:--------------------------------------------------------------------|:----|:-------------------|-----------:|:--|:----|:-----|-----------:|:--|
|                                                                     |     | US$                |            |   |     |      |            |   |
| Net cash used in operating activities                               |     |                    | (8,264,074 | ) |     |      | (1,766,135 | ) |
| Net cash used in investing activities                               |     |                    |    (53,045 | ) |     |      |    (69,848 | ) |
| Net cash provided by financing activities                           |     |                    |  8,675,790 |   |     |      |  1,881,493 |   |
| Net increase in cash and cash equivalents                           |     |                    |    358,671 |   |     |      |     45,510 |   |
| Effect of foreign currency translation on cash and cash equivalents |     |                    |     44,965 |   |     |      |    (18,962 | ) |
| Cash and cash equivalents, beginning of year                        |     |                    |     54,104 |   |     |      |     27,556 |   |
| Cash and cash equivalents, end of year                              |     |                    |    457,740 |   |     |      |     54,104 |   |

Operating activities

Net cash used in operating
activities was US$8,264,074 for the year ended December 31, 2024. The difference between NewGenIvf’s net loss of US